TRCT
FTH

Tower Research Capital (TRC)’s Faeth Therapeutics FTH Stock Holding History

Tower Research Capital (TRC)’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.2K Buy
+1,496
New +$29.9K ﹤0.01% 2788
2025
Q2 		– Sell
-270
Closed -$2.13K – 5555
2025
Q1 		$2.13K Sell
270
-2
-0.7% -$19 ﹤0.01% 4586
2024
Q4 		$2.67K Sell
272
-79
-23% -$793 ﹤0.01% 4795
2024
Q3 		$4.2K Sell
351
-3
-0.8% -$37 ﹤0.01% 4636
2024
Q2 		$4.39K Buy
354
+18
+5% +$374 ﹤0.01% 4788
2024
Q1 		$7.05K Sell
336
-86
-20% -$1.48K ﹤0.01% 4272
2023
Q4 		$5.84K Buy
422
+59
+16% +$805 ﹤0.01% 4799
2023
Q3 		$5.81K Sell
363
-11
-3% -$236 ﹤0.01% 4684
2023
Q2 		$8.52K Buy
374
+276
+282% +$8.08K ﹤0.01% 4423
2023
Q1 		$3K Sell
98
-8
-8% -$237 ﹤0.01% 5239
2022
Q4 		$3K Sell
106
-136
-56% -$4K ﹤0.01% 5231
2022
Q3 		$7K Buy
242
+23
+11% +$904 ﹤0.01% 4926
2022
Q2 		$10K Sell
219
-19
-8% -$712 ﹤0.01% 4482
2022
Q1 		$11K Buy
238
+57
+31% +$4.54K ﹤0.01% 4208
2021
Q4 		$21K Buy
181
+142
+364% +$21.2K ﹤0.01% 3619
2021
Q3 		$8K Sell
39
-32
-45% -$5.83K ﹤0.01% 4566
2021
Q2 		$14K Buy
71
+42
+145% +$10.4K ﹤0.01% 4186
2021
Q1 		$8K Buy
+29
New +$9.71K ﹤0.01% 4485

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Tower Research Capital (TRC)'s FTH Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Faeth Therapeutics (FTH) in Q1 2026: 1,496 shares worth $47.2K. The stake represents ﹤0.01% of the portfolio and ranks #2788 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in FTH as recently as Q1 2025.

Tower Research Capital (TRC) first reported a position in FTH in Q1 2021 and has held it in 18 quarters since. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Tower Research Capital (TRC) held 1,496 shares of Faeth Therapeutics worth $47.2K as of Q1 2026.
  • Faeth Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2788 holding.
  • Tower Research Capital (TRC) first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.